İçeriğe geç

Cris Bergerot, PhD

@crisbergerot.bsky.social did:plc:c7uckvugvdgto5clyo7p63uh

Advancing oncology care through research, innovation, and multidisciplinary collaboration. Passionate about patient-centered solutions, PROs, HRQOL, and evidence-based practices, w a focus on #GUOnc, #GeriOnc & #PallOnc #ASCO25 FCOI: http://bit.ly/344gKxq

Bluesky’a katılma tarihi:

Takipçi
545
Takip edilen
202
Post
98
Sıralamaya girdiği gün
0

Özet

Cris Bergerot, PhD (@crisbergerot.bsky.social), 28 Kasım 2024 tarihinde katılan bir Bluesky kullanıcısı. 545 takipçisi var, 202 hesabı takip ediyor ve 98 post paylaştı.

Sıralama geçmişi

Bu hesabın postlarının Debya günlük listesine girdiği en iyi günler.

Bu hesap henüz günlük sıralamaya girmedi.

Son beğendiği postlar

Bluesky ağındaki herkese açık beğeniler.

  • American Society of Clinical Oncology@ascocancer.bsky.social

    And the answer was ... D! Erdafitinib causes ocular toxicity; a baseline ophthalmic exam is required. Did you get it right? Let us know in the comments! Subscribe to ASCO-SEP® today: bit.ly/47OmqN7 ASCO members get 20% off; additional discounts available.

    Postu göster
  • American Society of Clinical Oncology@ascocancer.bsky.social

    New Living Guideline: Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I to III Breast Cancer. The new Living Guideline covers the use of medical therapies for stage I-III hormone receptor-positive, HER2-negative breast cancer. Learn more: https://bit.ly/4spJjjv

    Postu göster
  • American Society of Clinical Oncology@ascocancer.bsky.social

    Dr. Sumanta Pal of @cityofhope.bsky.social and @ryannipp.bsky.social of OU Health Stephenson Cancer Center discuss high-impact research presented at #ASCOQLTY26 on the latest episode of the #ASCODailyNews Podcast: https://bit.ly/4zg53kt

    Postu göster
  • International Kidney Cancer Coalition@ikccorg.bsky.social

    We are proud to continue our partnership with the American Association for Cancer Research (AACR) to support the AACR Scholar-in-Training Award! 🗓️ Application Deadline: 10 November 2026 🔗 Learn more and apply: buff.ly/yx1Y0QV

    Postu göster
  • KidneyCAN@kidneycan.bsky.social

    No two #kidneycancer journeys are the same. Built with KidneyCAN & Eisai, Kompass can help guide you to tailored resources and support that fit where you are today. Explore for yourself at KidneyCancerKompass.com.

    Postu göster

Daha fazlası için üye girişi yap

Blokladığı hesaplar

Bluesky’da bloklar herkese açık kayıtlardır.

Bu hesap kimseyi bloklamıyor.